Literature DB >> 1973354

The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine.

G Nesher1, T L Moore.   

Abstract

The mode of action of low-dose methotrexate (MTX) in rheumatoid arthritis (RA) is unclear. The effects of MTX are mediated primarily through inhibition of dihydrofolate reductase, resulting in a dose-dependent inhibition of purine and pyrimidine synthesis. Other folate-dependent metabolic pathways might be secondarily affected. One such pathway is the regeneration of methionine from homocysteine, with subsequent formation of the methyl donor S-adenosylmethionine (SAM) and polyamines, which are important in cell-mediated immune reactions. To assess whether MTX inhibits SAM and polyamine synthesis in lymphocytes, pokeweed mitogen-stimulated mononuclear cells from healthy donors were incubated with MTX. This resulted in decreased proliferation and IgG, IgM, and IgM rheumatoid factor synthesis. However, addition of folinic acid, methionine, SAM, or spermidine resulted in reversal of the MTX-mediated inhibition. These data suggest that MTX inhibits the folate-dependent pathway of methionine regeneration, thereby inhibiting SAM and polyamine synthesis. Since RA lymphocytes have increased concentrations of polyamines, the beneficial effects of MTX in RA may be related to its potential ability to reduce polyamine synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973354     DOI: 10.1002/art.1780330706

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

Review 1.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 2.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  Going with the flow: methotrexate, adenosine, and blood flow.

Authors:  B N Cronstein
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

4.  Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo.

Authors:  Yi-Cheng Wang; En-Pei Isabel Chiang
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

5.  Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells.

Authors:  B N Cronstein; M A Eberle; H E Gruber; R I Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis.

Authors:  C J Haagsma; H J Blom; P L van Riel; M A van't Hof; B A Giesendorf; D van Oppenraaij-Emmerzaal; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1999-02       Impact factor: 19.103

Review 7.  The advances of methotrexate resistance in rheumatoid arthritis.

Authors:  Jun Yu; Peng Zhou
Journal:  Inflammopharmacology       Date:  2020-08-05       Impact factor: 4.473

8.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Authors:  B N Cronstein; D Naime; E Ostad
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

Review 9.  Treatment of early diffuse systemic sclerosis skin disease.

Authors:  Tracy M Frech; Victoria K Shanmugam; Ami A Shah; Shervin Assassi; Jessica K Gordon; Faye N Hant; Monique E Hinchcliff; Virginia Steen; Dinesh Khanna; Cristiane Kayser; Robyn T Domsic
Journal:  Clin Exp Rheumatol       Date:  2013-07-23       Impact factor: 4.473

10.  Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.

Authors:  A Joseph; K Munroe; M Housman; R Garman; S Richards
Journal:  Clin Exp Immunol       Date:  2008-02-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.